prikaz prve stranice dokumenta Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
  Download
PDF 718.46 KB
Scientific paper - Original scientific paper
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
Clinical Research in Cardiology, 111 (2022), 5; 560-573. https://doi.org/10.1007/s00392-022-01996-2
(GLORIA-AF) Lip, Gregory Y. H.; ...; Kes, Vanja Basic; Kalan, Marica Bracic; Brkljacic, Diana Delic; Knezevic, Aleksandar; Kovacic, Dragan; Nazlić, Jurica; Persic, Viktor; Pivac, Nediljko; Poljakovic, Zdravka

Citations:
,
Cite this document

Lip, G. Y. H., Kes, V. B., Kalan, M. B., Brkljacic, D. D., Knezevic, A., Kovacic, D. ... Poljakovic, Z. (2022). Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. Clinical Research in Cardiology, 111. (5), 560-573. doi: 10.1007/s00392-022-01996-2

Lip, Gregory Y. H., et al. "Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry." Clinical Research in Cardiology, vol. 111, no. 5, 2022, pp. 560-573. https://doi.org/10.1007/s00392-022-01996-2

Lip, Gregory Y. H., Vanja Basic Kes, Marica Bracic Kalan, Diana Delic Brkljacic, Aleksandar Knezevic, Dragan Kovacic, Jurica Nazlić, Viktor Persic, Nediljko Pivac and Zdravka Poljakovic. "Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry." Clinical Research in Cardiology 111, no. 5 (2022): 560-573. https://doi.org/10.1007/s00392-022-01996-2

Lip, G. Y. H., et al. (2022) 'Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry', Clinical Research in Cardiology, 111(5), pp. 560-573. doi: 10.1007/s00392-022-01996-2

Lip GYH, Kes VB, Kalan MB, Brkljacic DD, Knezevic A, Kovacic D, and sur.. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. Clinical Research in Cardiology [Internet]. 2022 March 16 [cited 2025 April 05];111(5):560-573. doi: 10.1007/s00392-022-01996-2

G. Y. H. Lip, et al., "Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry", Clinical Research in Cardiology, vol. 111, no. 5, pp. 560-573, March 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:220:815775. [Accessed: 05 April 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
AuthorGregory Y. H. Lip
Author
...
AuthorVanja Basic Kes
AuthorMarica Bracic Kalan
AuthorDiana Delic Brkljacic
AuthorAleksandar Knezevic
AuthorDragan Kovacic
AuthorJurica Nazlić
AuthorViktor Persic
AuthorNediljko Pivac
AuthorZdravka Poljakovic
CollaborationGLORIA-AF
Author's institution(Sestre milosrdnice University Hospital Center)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract (english)
Background and purpose: Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods: In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3 years. The comparative analyses for (1) dabigatran vs rivaroxaban or... More apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Results: The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0 years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79–2.03), major bleeding 0.59 (0.40–0.88), myocardial infarction 0.68 (0.40–1.16), and all-cause death 0.86 (0.67–1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76–1.78), myocardial infarction 0.84 (0.48–1.46), major bleeding 0.98 (0.63–1.52) and all-cause death 1.01 (0.79–1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52–1.19), myocardial infarction 0.96 (0.63–1.45), major bleeding 1.54 (1.14–2.08), and all-cause death 0.97 (0.80–1.19). Conclusions: Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death. Less
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleClinical Research in Cardiology
Numberingvol. 111, no. 5, pp. 560-573
p-ISSN1861-0684
e-ISSN1861-0692
DOIhttps://doi.org/10.1007/s00392-022-01996-2
URN:NBNurn:nbn:hr:220:815775
Publication2022-03-16
Document URLhttps://link.springer.com/10.1007/s00392-022-01996-2
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-06-25 11:20:27
accessibility

closeAccessibilityrefresh

If you wish to permanently save changes, click on Save, if not - your settings will be reset when you restart the browser.